A putative acid metabolite of a novel highly effective antiparkinsonian agent, (4S,5R,6R)‐5,6‐dihydroxy‐4‐(prop‐1‐en‐2‐yl)cyclohex‐1‐ene‐1‐carboxylic acid (5), was synthesized for the first time. Several synthetic approaches based on different transformations of O‐bearing monoterpenoids of the pinane and p‐menthane series were developed and tested in the course of the study. Acid 5 was synthesized
新型高效抗帕
金森病药物的推定酸代谢物(4 S,5 R,6 R)‐5,6 ‐二羟基‐ 4‐(丙‐ 1 ‐‐‐‐ 2‐yl)环己基‐1‐ ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐首次合成的
羧酸(5)。在研究过程中开发并测试了几种基于the烷和对-薄荷烷系列的含氧单
萜类化合物的不同转化的合成方法。酸5是从市售的单
萜类化合物(-)-马鞭草酮合成的,分8个步骤,总收率为4.4%。